

Translation

## **Hubei Medical Products Administration**

### **Notice on Drug GMP Compliance Inspection Results**

No.: E GMP No. 2022-22

Drug marketing authorization holder	Wuhan Humanwell Pharmaceutical Co., Ltd.
Scope/variety of inspection	Lyophilized powder for injection and small-volume injection
Inspected site	No. 8 Biopark Road, East-Lake New Technology Development Zone, Wuhan, Hubei, China
Inspected manufacturing workshop/line	Manufacturing line (2) of lyophilized powder for injection in workshop 2 for lyophilized powder for injection Manufacturing line (2) of small-volume injection in workshop 2 for small-volume injection
Duration of inspection	From Mar. 22, 2022 to Mar. 25, 2022
Conclusion of inspection	Upon review, the drug GMP compliance inspection met the requirements of Good Manufacturing Practice (revised in 2010), and the inspection result is hereby notified.
Sent to	Wuhan Humanwell Pharmaceutical Co., Ltd.
Cc	Wuhan Branch of Hubei Medical Products Administration
Remark	

Stamp: Hubei Medical Products Administration

Jun. 20, 2022